drugset / Trial / NCT05519540
PK Study of Xevinapant (Debio 1143) in Healthy East Asian Participants
Phase 1
Completed
24 enrolled
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study was to evaluate the pharmacokinetics (PK) of Xevinapant (Debio 1143) and its metabolite D-1143-MET1 as well as safety and tolerability of Xevinapant (Debio 1143) in healthy East Asian participants.
Timeline
- Start
- 2022-09-26
- Primary completion
- 2023-04-21
- Completion
- 2023-04-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Xevinapant | Small molecule | 200 mg | Oral |
Indications
No indication recorded.